Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,663
  • Shares Outstanding, K 8,750
  • Annual Sales, $ 70 K
  • Annual Income, $ -71,910 K
  • 36-Month Beta 2.24
  • Price/Sales 119.47
  • Price/Cash Flow N/A
  • Price/Book 5.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.22
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.91
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -2.10
  • Prior Year -1.68
  • Growth Rate Est. (year over year) +45.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.88 +12.39%
on 02/11/19
1.19 -16.89%
on 01/16/19
-0.16 (-14.00%)
since 01/15/19
3-Month
0.80 +23.63%
on 12/24/18
1.86 -46.83%
on 11/27/18
-0.33 (-25.08%)
since 11/15/18
52-Week
0.80 +23.63%
on 12/24/18
15.60 -93.66%
on 02/16/18
-13.65 (-93.24%)
since 02/15/18

Most Recent Stories

More News
Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as...

RGLS : 0.99 (unch)
Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a...

RGLS : 0.99 (unch)
Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advanced Energy Industries,...

AEIS : 51.16 (+0.87%)
HK : 1.89 (+5.00%)
NNBR : 10.35 (+0.58%)
ALTR : 34.64 (+1.41%)
RMBS : 10.15 (+0.50%)
RGLS : 0.99 (unch)
Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it presented new data on...

RGLS : 0.99 (unch)
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 24.36% and -10.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 0.99 (unch)
Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the third...

RGLS : 0.99 (unch)
Regulus Announces Successful Restructuring of Sanofi Collaboration

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has amended and restructured...

RGLS : 0.99 (unch)
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGLS : 0.99 (unch)
Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from...

RGLS : 0.99 (unch)
Traders Get Bullish on Shares of Regulus Therapeu, Shares Up 36.6% (RGLS)

Regulus Therapeu (NASDAQ:RGLS) is one of today's best performing low-priced stocks, up 36.6% to $2.50 on 2.5x average daily volume. Thus far today, Regulus Therapeu has traded 1.3 million shares, vs....

RGLS : 0.99 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 1.10
1st Resistance Point 1.04
Last Price 0.99
1st Support Level 0.94
2nd Support Level 0.89

See More

52-Week High 15.60
Fibonacci 61.8% 9.95
Fibonacci 50% 8.20
Fibonacci 38.2% 6.45
Last Price 0.99
52-Week Low 0.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar